CD274 and cancer: Immune checkpoint inhibitors (ICIs), including PD-L1/PD-1 inhibitors, have recently emerged as potent therapies for a wide range of cancers, many of which are first-line treatments and can even improve outcomes for malignancies considered incurable (1).